Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histamine H1 receptor

7

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1996

4

1997

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Allergic conjunctivitis

7

Seasonal allergic rhinitis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

7

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kyowa Hakko Kirin

4

Kanebo

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

5

EVMPD

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SENSORY ORGANS

2

RESPIRATORY SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OPHTHALMOLOGICALS

2

NASAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DECONGESTANTS AND ANTIALLERGICS

2

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antiallergics

2

Antiallergic agents, excl. corticosteroids

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

OLOPATADINE

D27V6190PM

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1996

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Seasonal allergic rhinitis

Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 rec...

eptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

EMEDASTINE

9J1H7Y9OJV

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

Olopatadine Hydrochloride, (E)-

B5XL4FL7QZ

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1996

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Seasonal allergic rhinitis

Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 rec...

eptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

OLOPATADINE, (E)-

KU3MJP076O

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1996

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Seasonal allergic rhinitis

Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 rec...

eptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

OLOPATADINE HYDROCHLORIDE

2XG66W44KF

Export Data
Search for Structure

Status:

US Approved Rx (2015)

First approved in 1996

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Seasonal allergic rhinitis

Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 rec...

eptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

EMEDASTINE MONOFUMARATE

1P089Y932J

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

EMEDASTINE DIFUMARATE

42MB94QOSM

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1997

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histamine H1 receptor

Conditions:

Allergic conjunctivitis

Emedastine is an antihistaminic agent, which was approved by FDA for the treatment of allergic conjunctivitis (Emadine brand name). The drug acts selectively on H1 receptors with lower affinity to H2 and H3 subtypes. Emedastine has a relatively unfav...

orable CNS effect profile. A small percentage of patients reported somnolence as an adverse effect after administration.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1